The 2019 Annual Meeting of Chinese Society of Clinical Oncology (CSCO) was held as scheduled in Xiamen from September 18 to 22, 2019. As a top and authoritative academic event focusing on oncology in China, it has attracted almost 30,000 experts and physicians and 300 enterprises this year to participate in conferences and exhibitions. On September 19, a satellite meeting on the theme of "The Right Way to Go Far - Standard Regulation of CINV" was held under the leadership of Hansoh Pharma.
During the meeting, experts from the field of oncology gave keynote presentations on the importance of standard regulation of CINV (chemotherapy-induced nausea and vomiting), the application of Fosaprepitant in standard regulation of CINV and other topics, and conducted in-depth discussions on hot and focus issues in the clinical treatment of CINV.
Professor Luo Suxia from Henan Cancer Hospital noted that chemotherapy is a key means for cancer treatment, and vomiting and nausea are among the most common and subjectively painful adverse reactions caused by chemotherapy. CINV will not only damage the living quality of patients and their treatment compliance, but also cause metabolic dysfunction, nutritional disorder, and loss of weight in serious cases, resulting in unsatisfactory tumor control.
At present, most CINV drugs clinically used in China are 5-HT3 receptor antagonists. Although such drugs work well in stop vomiting, they can hardly provide completely effective control due to the different severity of vomiting. Therefore, they need to be taken along with other types of drugs, while the emergence of neurokinin-1 (NK-1) receptor antagonists remedies the defects of such drugs.
According to Professor Xu Qing from the Tenth People's Hospital Affiliated to Tongji University, Fosaprepitan is a selective, high affinity antagonist of human substance P/NK-1 receptor and a necessary antiemetic drug for highly emetic chemotherapy (HEC) unanimously recommended by domestic and foreign guidelines; it works through a novel mechanism by blocking the brain's signals of nausea and vomiting, and can be used with 5-HT3 receptor antagonist to improve antiemetic effects. Multiple clinical researches at home and abroad show that Fosaprepitant can effectively prevent CINV and provide good safety in clinical application. Fosaprepitant Dimeglumine (brand name: Tanneng) developed by Hansoh Pharma is characterized by accurate dosage, rapid onset of action and ease of use, and after its launch, will bring a new, safe, effective and accessible treatment option for CINV prevention to patients under chemotherapy in China.
At present, no Fosaprepitant has yet been approved for marketing in China; Hansoh Pharma’sTanneng will come into the market soon and is expected to satisfy the needs of cancer chemotherapy patients in clinical medication and improve their living quality after its launch.
